Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma

Opinion statement Mantle cell lymphoma is a rare and incurable non-Hodgkin lymphoma with a heterogenous clinical presentation. Typically, treatment consists of frontline chemoimmunotherapy induction with or without autologous stem cell transplant (ASCT) as consolidation. However, this approach has the propensity to increase short- and long-term toxicities, such as secondary malignancies, without being curative. Genomic profiling of MCL will allow for greater impact of new targeted therapies in the future and may become a helpful tool to guide treatment. Based on the data discussed, use of non-chemotherapy options may become the preferred approach for frontline therapy as opposed to conventional chemotherapy and hematopoietic stem cell transplants.

Automated summary

Mantle cell lymphoma is a rare and incurable non-Hodgkin lymphoma with heterogeneous clinical presentation. Current frontline treatment approaches may increase toxicities without providing a cure, leading researchers to explore genomic profiling for potential targeted therapies in the future. Non-chemotherapy options may become more favored for frontline therapy over conventional chemotherapy and stem cell transplants based on the discussed data.